Shares of

ICU Medical

(ICUI) - Get Report

were among the best-performing health-related stocks Wednesday, jumping 11% after the medical device company posted higher-than-expected first-quarter earnings and lifted its full-year earnings outlook.

The company earned $6.4 million, or 41 cents a share, on revenue of $48.8 million. Analysts polled by Thomson First Call expected earnings of 33 cents a share. During the year-earlier period, the company earned $4.4 million, or 30 cents a share, on revenue of $27.1 million. "The company's top-line performance was driven mainly by strong demand for our customer IV systems and by our critical care product lines," the company said.

Looking ahead, ICU Medical now sees 2006 earnings of $1.56 to $1.59 a share, a dime higher than its earlier forecast. Analysts project earnings of $1.50 a share. The company predicts revenue of $188 million to $190 million. Shares were trading up $3.85 to $40.08.

Usana Health Sciences

(USNA) - Get Report

fell 7% after the maker of nutritional products turned in lower-than-expected first-quarter earnings and issued a tepid second-quarter sales guidance. The company reported first-quarter earnings of $9.6 million, or 50 cents a share, up from $8.9 million, or 45 cents a share, a year earlier. Revenue rose to $89.7 million from $76.6 million.

For the second quarter, Usana projects earnings of 54 cents to 56 cents share, in line with analysts' estimate of 55 cents. The company sees revenue of $92 million to $94 million, compared with Wall Street's forecast of $94.8 million. Shares were down $2.81 to $38.98.

Shares of

Genzyme

( GENZ) slid 8% after the drugmaker posted disappointing first-quarter results. The company earned $101 million, or 37 cents a share, on revenue of $730.8 million. Excluding certain items, the company earned $156.5 million, or 59 cents a share. Analysts expected earnings of 63 cents a share on revenue of $749.1 million. Excluding items, the company last year earned $131.1 million, or 51 cents a share, on revenue of $629.9 million.

Despite the first-quarter stumble, Genzyme reiterated its 2006 earnings and sales outlook. Genzyme continues to predict earnings, excluding items, of $2.65 to $2.75 a share. Analysts project earnings of $2.75 a share. The company anticipates revenue of $3.1 billion to $3.3 billion, bracketing analysts' mean estimate of $3.21 billion. Shares were down $5.09 to $60.69.

Shares of

Lifecore Biomedical

( LCBM) jumped 13% after the medical device company posted third-quarter results that topped forecasts. The company earned $2.2 million, or 16 cents a share, for the quarter ended March 31, topping analysts' earnings-per-share forecast by 3 cents. Lifecore posted revenue of $16.8 million, surpassing the Wall Street estimate of $15.7 million. Last year, the company reported third-quarter earnings of $2.1 million, or 15 cents a share, on revenue of $14.2 million.

Looking ahead, Lifecore sees fiscal fourth-quarter earnings of 16 cents to 18 cents a share on revenue of $16.8 million to $17.2 million. Analysts project earnings of 18 cents a share on revenue of $17.6 million. Shares were up $1.65 to $14.31.

Illumina

(ILMN) - Get Report

climbed 11% after the genetics diagnostics company posted first-quarter results that blew by estimates. The company reported a loss of $104,000, or less than a penny a share, on revenue of $29.1 million. Excluding stock-based compensation costs, the company earned $3 million, or 7 cents a share. Analysts expected earnings of 1 cent a share, before items, on revenue of $23.8 million. A year ago, the company reported a first-quarter loss of $1.2 million, or 3 cents a share, on revenue of $15.1 million.

For the second quarter, Illumina forecast earnings of 7 cents to 9 cents a share and revenue of $31 million to $33 million. Analysts project earnings of 3 cents a share and revenue of $27.8 million. Shares were up $2.95 to $28.70.

Other health care volume movers included

UnitedHealth Group

(UNH) - Get Report

, down $1.30 to $48.37;

Amgen

(AMGN) - Get Report

, down $2.84 to $68.13;

Pfizer

(PFE) - Get Report

, down 5 cents to $24.88;

Boston Scientific

(BSX) - Get Report

, down 2 cents to $21.72;

Caremark Rx

( CMX), down $1.56 to $44.79;

Medtronic

(MDT) - Get Report

, down 17 cents to $49.12;

Johnson & Johnson

(JNJ) - Get Report

, down 26 cents to $57.87;

Merck

(MRK) - Get Report

, down 9 cents to $34.39;

Bristol-Myers Squibb

(BMY) - Get Report

, down 34 cents to $24.49; and

Schering-Plough

( SGP), up 12 cents to $18.78.